Clinical Trials
290 trialsA Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
AbbVie
ROXI-CAT-I
Regeneron Pharmaceuticals
GLORIOSA
AbbVie
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Amgen
A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer
Hoffmann-La Roche
ROSY-D
AstraZeneca
SUNRAY-01
Eli Lilly and Company
SaLuDo
PharmaMar
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
Amgen
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
AbbVie
UmbrellaMAX
Hoffmann-La Roche
EV-309
Astellas Pharma Inc
EPCOREā¢FL-2
Genmab
Spotlight
Astellas Pharma Inc
BRIDGES
GT Medical Technologies, Inc.
LUCERNA
Astellas Pharma Inc
IMbrella B
Hoffmann-La Roche
CodeBreaK 301
Amgen
COMBI-AD
Novartis
SERENA-6
AstraZeneca
GLOW
Astellas Pharma Inc
ROSY-O
AstraZeneca
IPAX BrIGHT
Telix Pharmaceuticals (Innovations) Pty Limited
QUATRO-APL
Quetzal Therapeutics
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
Bayer
A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
Hoffmann-La Roche
ENGOT-EN5
Karyopharm Therapeutics Inc
Bevonescein for Intra-Operative Nerve Visualization in Head and Neck Surgery
Alume Biosciences, Inc.
A Prospective Pivotal Study to Evaluate the Efficacy and Safety of AvastinĀ® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients
NaviFUS Corporation
BRIA-ABC
BriaCell Therapeutics Corporation
An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)
Hoffmann-La Roche
ROSY-T
AstraZeneca
RC-102
Resilience
ESCALADE
Acerta Pharma BV
TirbAKare
Almirall, S.A.
ROXI-CAT-II
Regeneron Pharmaceuticals
TRANSFORM-1
AbbVie
ADVANCED-3
Protara Therapeutics
BOOST
Relmada Therapeutics, Inc.
RESCUE
Relmada Therapeutics, Inc.
RESCUE
Relmada Therapeutics, Inc.
AcceleRET-Lung
Hoffmann-La Roche
FALCON
AstraZeneca
COLUMBUS
Pfizer
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
Daiichi Sankyo
Bintrafusp Alfa Program Rollover Study
EMD Serono
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
AbbVie
OVELIA
Tolmar Inc.
Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
Tolmar Inc.
TRANSFORM-2
AbbVie